Instituto Veracruz de Pesquisa e Tratamento da Dependência Química

VeraCruz Brasil (Instituto Veracruz de Pesquisa e Tratamento da Dependência Química) is a Brazilian biotechnology and clinical research organization focused on developing innovative treatments for Substance Use Disorders (SUD) and mental health conditions. The company is pioneering the clinical development of ibogaine, a psychoactive alkaloid derived from Voacanga africana, for the treatment of cocaine and crack addiction. VeraCruz Brasil is currently conducting a Phase II/III randomized, multicenter clinical trial in Brazil, positioning itself at the forefront of psychedelic medicine and neuroscientific research in Latin America. The institute integrates specialized clinical care with rigorous scientific protocols to advance evidence-based therapies for chemical dependency. Through strategic partnerships with academic institutions and regulatory bodies, the company aims to establish a new standard of care for addiction treatment.